Log In
BCIQ
Print this Print this
 

ToleraCyte

  Manage Alerts
Collapse Summary General Information
Company Fate Therapeutics Inc.
DescriptionCD34-positive cells modulated ex vivo with 16, 16-dimethyl prostaglandin E2 (PGE2) and dexamethasone
Molecular Target
Mechanism of Action 
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetes
Indication DetailsTreat Type I diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today